A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
This open label, multi-centre phase II study will assess the efficacy and safety of single
agent SC10914 in metastatic breast cancer patients with gBRCA 1/2 mutations.